Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2001 Jul;2(7):896-9.Links

Helivax Antex Biologics.

Giudice GD.

IRIS Research Center, Chiron SpA, Siena, Italy. giuseppe_del_giudice@chiron.it

Antex Biologics is developing an oral vaccine against Helicobacter pylori infection as a potential treatment and prophylaxis for gastric ulcers. The vaccine incorporates a mucosal adjuvant and is in phase II trials [376332]. Enrollment for the trial was completed in September 2000 and results are expected in 2001 [382128]. In July 2000, Antex started a two-part phase Ib/II clinical trial of the vaccine. The first part was an open-label study to assess the general safety of the vaccine in uninfected and asymptomatic Helicobacter pylori-infected individuals. The second part was an expanded placebo-controlled study to evaluate safety and immunogenicity of the vaccine. The vaccine was generally well-tolerated and it generated an immune response in both infected and non-infected individuals [312681].

PMID: 11757787 [PubMed - indexed for MEDLINE]

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on